
### ACHIEVING HEALTH EQUITY THROUGH RACE-NEUTRAL SPIROMETRY

Understanding the 2023 ATS position on Pulmonary Function Testing

## **Normalizing Lung Function for Spirometry**



The idea that lung capacity of black persons is lower compared to whites is an example of scientific racism.<sup>1</sup> A race based correction factor is applied to spirometry, **reducing** the normal reference range of lung capacity by **10%–15%** for **Black** or **African-American patients**.<sup>2</sup>

Until recently, **social determinants of health** were largely **overlooked** and **technology has masked** how race-based algorithms are applied.<sup>2,3</sup>

### The Evolution of Race-neutral Spirometry

In 2023, **ATS** issued **new clinical recommendations calling for the use of race-neutral equations in spirometry**, a change representing an evolution in thought supported by recent evidence.<sup>4</sup> A race-neutral reference equation provides better or equivalent relationships between spirometry and symptoms, airway structure, emphysema, and functional capacity.<sup>1</sup>




AstraZen

#### **RACE DOES NOT PREDICT GENETIC ANCESTRY**

Race is a social construct comprising broad, poorly defined categories that neither reliably predict genetic ancestry nor consistently unite people biologically."

Collective statements from AAFP, ATS, AMA, AAP<sup>1,2,5,6</sup>



Classifying patients by race alone drives thinking away from the examination of other social, environmental, and genetic factors as drivers of disease.<sup>6</sup> Genetic associations with pulmonary function do not provide evidence for the use of race or ethnicity in PFT interpretation.<sup>1</sup>

# Race-adjusted spirometry can be harmful because it

- May lead to the underdiagnosis and misdiagnosis of pulmonary disease in racial minority patients<sup>2,7,8</sup>
- Can reduce access to effective treatments<sup>1,7,9,10</sup>
- Impacts clinical risk of morbidity and mortality<sup>1,11,12</sup>

#### Misdiagnosis and Decreased Access to Care



AstraZ

## **ACT on Health Equity**

**EDUCATE** leaders at your institution on how race-neutral spirometry could impact quality of care.

**ADVOCATE** for the implementation of ATS recommendations in lung function assessment and determine how race adjustment can be removed.

**EVALUATE** how you can best support patients whose diagnosis may be changed with race-neutral spirometry.

Abbreviations: AAFP: American Academy of Family Physicians; AAP: American Academy of Pediatrics; AMA: American Medical Association; ATS: American Thoracic Society; PTI: pulmonary function test.

. Bhakta NR, Bime C, Kaminsky D, et al. Race and ethnicity in pulmonary function test Interpretation. *An Official American* Thoracic Society Statement. *Am J Respir Crit Care Med.* 2023;207(8):978-995. doi:10.1164/rccm.20230-0781051-2. Reddick B. leconsidering the use of race in spirometry interpretation. *Am D Mysician 2023*;107(3):222-223. Braun L Race correction and spirometry: why history matters. *Chest.* 2021;159(4):1670-1675. 4. American Thoracic Society ATS publishes official statement in race, ethnicity and pulmonary function test interpretation. *PM Systems 2023*; 107(3):222-223. Braun L Race correction and spirometry: why history matters. *Chest.* 2023;159(4):1670-1675. 4. American Medical Association. New MA policies recognize race as a social, not biological, construct (Press Release). Nowmber 16, 2020. Accessed January 26, 2024. <u>www.ama-assn.org/press-center/press-releases/new-ama-policies-recognize-race-social-not-biological-construct.</u> 6. Wright J, avis W, Joseph M, et al. Eliminating race-based medicine. *Pediatriss.* 2022;150(1):e202205798. doi:10.1542/peds.2022-057998. 7. Anderson M, Malhotta A, No A, et al. Could routine race-adjustment of spirometers exacerbate racial dispatcing ecowery? *Lancet Respir Med.* 2021;9(2):124-125. doi:10.1016/52213-2600(2)30571-3. 8. Moffett A, Bowerman C, Stanojevic S, et al. Global, race-neutral reference equations and pulmonary function test Interpretation. *JMAM Retw. Dev.* 2023;6(6):e2316174. Joi:10.1001/jamanetworkopen. 2023;16(1):e202057998. doi:10.1542/peds.202-507998. doi:10.1542/rccm.202107/9120-824. *Bay Med.* 2023;16(9):124-125. doi:10.1016/s2213-2600(2):0571-3. 8. Moffett A, Bowerman C, Stanojevic S, et al. Global, race-neutral reference equations and pulmonary function test Interpretation. *JMAN Retw.* 2023;6(6):10:1002/jhm.12974. Joi:10.10101/jamanetworkopen. 2023;16(9):452-447. doi:10.1016/j1201-441. Tester 2002;40(1):40:456-447. doi:10.1016/j1201-44. 2023;40(3):40:40. *M Resp. Edi.* 2023;205(6):700-710. Joi:10.1164/rccm.202107-16120C

©2024 AstraZeneca. All rights reserved. US-88078 Last Updated 3/24